TNF and interstitial lung disease: The objective of this nationwide, retrospective study was to estimate the incidence of ILD in patients with RA treated with different b/tsDMARDs and to compare the risk of developing ILD between patients treated with different b/tsDMARDs and adalimumab (the most commonly prescribed TNF-α inhibitor for RA in our data set).